Gastric cancer treatment to rocket to $4.4 billion
London | 23 December 2015

The gastric cancer treatment market will increase to $4.4 billion by 2024, says report by GlobalData.

GlobalData’s report predicts that the market will rise from $1.3 billion in 2014 to the reported figures, driven by the introduction of premium-priced therapies for advanced gastric cancer and, as a consequence, the increased uptake of therapy and a longer treatment duration.

The PharmaPoint report stated that the main drivers of the expansion of the market includes the launch of premium priced metastatic therapies such as Eli Lilly’s Cyramza (ramucirumab) and Merck & Co.’s Keytruda (pembrolizumab) and BMS’ Opdivo (nivolumab).

GlobalData expects, by the end of the forecast period, for Cyramza to dominate the market with an overall 37 percent share of the gastric cancer treatment market.

Key patent expiry of Herceptin will also lead to biosimilar entries expected to start in 2017.

Author: Tammy Facey



More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences
IPPRO ARCHIVES
BACK ISSUES ONLINE
COMPANY INFO
ABOUT US

THE TEAM


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization